Sparks commentary - Herantis Pharma

Healthcare

Sparks - Herantis Pharma

More on this equity
Herantis Pharma (HEL: HRTIS) – New €4.2m raise to support Phase II plans
Published by Jyoti Prakash, CFA

Herantis Pharma has completed a directed share issue, raising gross proceeds of €4.2m to support development of its potentially disease-modifying Parkinson’s disease (PD) therapy candidate HER-096. The company issued 2.41m new shares at €1.75 per share, representing a 15.7% discount to the recent volume-weighted average price. Proceeds will fund preparations for the planned Phase II study, partnership discussions and general corporate activities. Management views the financing as a timely and cost-efficient alternative to a rights issue, providing funding certainty amid volatile biotech markets. The new shares are expected to be listed shortly on Nasdaq First North Growth Market Finland.

The company reported positive Phase Ib data for HER-096 in October 2025 and recently presented biomarker data from the study, which supported HER-096’s mechanism of action as a potential disease-modifier for PD. The company plans to launch the Phase II trial in 2026.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.